Proposed serialisation legislation would place additional requirements on biopharm and, in all likelihood, drive demand for service providers capable of handling the work. Increased demand presents a revenue opportunity for contract packagers but there are also challenges and risks.
Contract packagers must be flexible enough to meet the needs of different clients, from the big pharma with its own serialisation numbers to the biotech looking for an end-to-end service, Steve Wood, CEO of Covectra, told Outsourcing-Pharma.
Failure to meet these needs will result in loss of contracts, said Wood. This will begin happening “very soon” as biopharm launches pilot projects ahead of the “huge, huge undertaking” of serialising full product portfolios.